afm-13
affimed
['peripheral t-cell lymphoma', 'afm13', 't-cell lymphoma', 'lymphoma', 'afm13 ']
the bispecific antibody afm13 elicits responses in patients with relapsed/refractory peripheral t-cell lymphoma, a phase 2 study presented at aacr 2023 suggests. #aacr23 
https://t.co/bi63MIVP5D is a resource offering oncology health care professionals practical information about the changing clinical landscape.